Novartis AG ADR (NVS)vsVarex Imaging Corp (VREX)
NVS
Novartis AG ADR
$160.32
-0.04%
HEALTHCARE · Cap: $303.67B
VREX
Varex Imaging Corp
$18.27
-0.65%
HEALTHCARE · Cap: $783.03M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 6532% more annual revenue ($57.36B vs $865.00M). NVS leads profitability with a 17.5% profit margin vs 2.6%. NVS appears more attractively valued with a PEG of 3.84. VREX earns a higher WallStSmart Score of 55/100 (C-).
NVS
Hold48
out of 100
Grade: D+
VREX
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.8%
Fair Value
$95.76
Current Price
$160.32
$64.56 premium
Margin of Safety
+13.6%
Fair Value
$15.76
Current Price
$18.27
$2.51 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 34.3%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Earnings expanding 453.4% YoY
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
Premium valuation, high expectations priced in
3.7% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : VREX
The strongest argument for VREX centers on EPS Growth, Price/Book.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : VREX
The primary concerns for VREX are P/E Ratio, Revenue Growth, Altman Z-Score. Thin 2.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
VREX carries more volatility with a beta of 1.03 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VREX scores higher overall (55/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Varex Imaging Corp
HEALTHCARE · MEDICAL DEVICES · USA
Varex Imaging Corporation designs and manufactures X-ray imaging components. The company is headquartered in Salt Lake City, Utah.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?